AstraZeneca Finance LLC, founded in 2009 and headquartered in the United Kingdom, serves as the financing arm of pharmaceutical giant AstraZeneca PLC. The company is dedicated to facilitating funding for its parent organization through a variety of financial instruments and services. Key offerings include corporate bonds, loans, and debt issuances, aimed at supporting AstraZeneca’s research and development efforts globally.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| AZN 1.20% 2026-05-28 USDAstraZeneca Finance LLC | United States | 2026-05-28 | 1.200 | 3.63 |
| AZN 1.75% 2028-05-28 USDAstraZeneca Finance LLC | United States | 2028-05-28 | 1.750 | 3.75 |
| AZN 2.25% 2031-05-28 USDAstraZeneca Finance LLC | United States | 2031-05-28 | 2.250 | 4.03 |
| AZN 3.12% 2030-08-05 EURAstraZeneca Finance LLC | United States | 2030-08-05 | 3.121 | 2.71 |
| AZN 3.28% 2033-08-05 EURAstraZeneca Finance LLC | United States | 2033-08-05 | 3.278 | 3.14 |
| AZN 4.80% 2027-02-26 USDAstraZeneca Finance LLC | United Kingdom | 2027-02-26 | 4.800 | 3.83 |
| AZN 4.85% 2029-02-26 USDAstraZeneca Finance LLC | United Kingdom | 2029-02-26 | 4.850 | 3.75 |
| AZN 4.88% 2028-03-03 USDAstraZeneca Finance LLC | United States | 2028-03-03 | 4.875 | 3.72 |
| AZN 4.88% 2033-03-03 USDAstraZeneca Finance LLC | United States | 2033-03-03 | 4.875 | 4.23 |
| AZN 4.90% 2030-03-03 USDAstraZeneca Finance LLC | United States | 2030-03-03 | 4.900 | 3.90 |
| AZN 4.90% 2031-02-26 USDAstraZeneca Finance LLC | United Kingdom | 2031-02-26 | 4.900 | 4.02 |
| AZN 5.00% 2034-02-26 USDAstraZeneca Finance LLC | United States | 2034-02-26 | 5.000 | 4.38 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
AstraZeneca Finance LLC first commenced bond issuances in the same year of its establishment, effectively aligning its funding strategies with the growth of AstraZeneca PLC. Notable bond offerings include a $1 billion issuance in 2021, which was utilized to finance innovative drug development projects. Currently, their bonds yield around 2.5%, competitive with industry averages, and are noted for their green financing features, supporting sustainability initiatives in healthcare. Recent news highlights plans for further bond issuances to bolster funding for upcoming clinical trials.